IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

PI3K delta (PI3Kδ) inhibitors are used to treat lymphomas but safety concerns and limited target selectivity curbed their clinical usefulness. PI3Kδ inhibition in solid tumors has recently emerged as a potential novel anticancer therapy through the modulation of T-cell responses and direct antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Zoë, Tarantelli, Chiara, Civanelli, Elisa, Cascione, Luciano, Spriano, Filippo, Fraser, Amy, Shah, Pritom, Nomanbhoy, Tyzoon, Napoli, Sara, Rinaldi, Andrea, Niewola-Staszkowska, Karolina, Lahn, Michael, Perrin, Dominique, Wenes, Mathias, Migliorini, Denis, Bertoni, Francesco, van der Veen, Lars, Di Conza, Giusy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103717/
https://www.ncbi.nlm.nih.gov/pubmed/37066023
http://dx.doi.org/10.1158/2767-9764.CRC-22-0477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103717/
https://www.ncbi.nlm.nih.gov/pubmed/37066023
http://dx.doi.org/10.1158/2767-9764.CRC-22-0477

Ejemplares similares